Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + nivolumab + ipilimumab versus nivolumab + ipilimumab in previously untreated advanced renal cell carcinoma
NL-OMON49041Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cabozantinib, nivolumab and ipilimumab in renal cell carcinoma (RCC) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Progression-free survival. Started May 2020; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON49041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49041.